Pirfenidone

Status
Phase 2
Condition
Systemic Sclerosis ILD
Intervention Type
Oral Drug
Funder Type
Organization | University

Drug Details

Pirfenidone (Esbriet®, Pirfenex®, Pirespa®): Pirfenidone is an antifibrotic and anti-inflammatory drug approved to treat IPF in the US, Europe, Canada, Asia, and Australia. In clinical trials, pirfenidone has been shown to slow progression of mild-to-moderate idiopathic pulmonary fibrosis. It is taken by mouth three times a day. 

Study Purpose

A Phase II multi-center, double-blind, parallel group, randomized and placebo-controlled clinical trial addressing the treatment of patients with active and symptomatic Scleroderma-related interstitial lung disease (SSc-ILD).

Find a Clinical Trial
footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >